Browsing by Author "Aksoy, Sercan"

Filter results by typing the first few letters
Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    Balance after stapedotomy: Analysis of balance with computerized dynamic posturography
    (Wiley, 2009-06) Aksoy, Sercan; Özmen, Suay; Saraç, Sibel; Sennaroğlu, Levent; Gürsel, Burcu; Özmen, Ömer Afşin; Uludağ Üniversitesi/Tıp Fakültesi/Kulak Burun Boğaz Anabilim Dalı.; 0000-0002-9698-0546; A-1452-2019; 55407733900
    The aim of this study was to investigate vestibular symptoms and their effect on the balance in otosclerosis patients undergoing stapedotomy operations. Prospective study at an academic tertiary referral centre. Thirty-three patients undergoing stapedotomy were included in the study. Sensory organisation test (SOT) protocol of computerized dynamic posturography was used to analyse the balance in patients preoperatively, in the first postoperative week and the first postoperative month. Postoperative vestibular symptoms were analysed with a grading system. Audiograms were obtained preoperatively and 1 month after the operation. Preoperatively, all patients were asymptomatic when considering the vestibular system; however, eight of them got low SOT scores on vestibular examination. Postoperatively 82% of the patients had vestibular complaints in variable severity. In the first week, all but one patient become asymptomatic. This patient recovered by the end of postoperative second week. However, a significant drop in SOT scores was encountered at the first week testing (Student's T-test, P = 0.001). One month after the operation, all patients were asymptomatic and SOT scores recovered at least to preoperative level. Neither patient characteristics, nor audiological findings were found to be correlated with vestibular changes. Stapedotomy causes a temporary balance loss in a high percentage of patients which then recover to their former levels in the first postoperative month.
  • No Thumbnail Available
    Item
    Comparison of natural in-vitro fertilization cycles with and without the use of GnRH antagonists for poor responder patients
    (Oxford University, 2012) Aksoy, Sercan; Yakın, Kayhan; Çalışkan, Seval; Salar, Zeki; Urman, Bülent; Ata, Barış; Uludağ Üniversitesi/Tıp Fakültesi/Kadın Hastalıkları ve Doğum Anabilim Dalı.
  • No Thumbnail Available
    Publication
    Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
    (Future Medicine Ltd, 2023-05-03) Kahraman, Seda; Erul, Enes; Seyyar, Mustafa; Gumusay, Ozge; Bayram, Ertugrul; Demirel, Burcin Cakan; Acar, Omer; Aksoy, Sercan; Baytemur, Naziyet Kose; Sahin, Elif; Cabuk, Devrim; Basaran, Gul; Paydas, Semra; Yaren, Arzu; Guven, Deniz Can; Erdogan, Atike Pinar; Demirci, Umut; Yasar, Alper; Bayoglu, Ibrahim Vedat; Hizal, Mutlu; Gulbagci, Burcu; Paksoy, Nail; Davarci, Sena Ece; Yilmaz, Funda; Dogan, Ozlem; Orhan, Sibel Oyucu; Kayikcioglu, Erkan; Aytac, Ali; Keskinkilic, Merve; Mocan, Eda Eylemer; Unal, Olcun Umit; Aydin, Esra; Yucel, Hakan; Isik, Deniz; Eren, Onder; Uluc, Basak Oyan; Ozcelik, Melike; Hacibekiroglu, Ilhan; Aydiner, Adnan; Demir, Hacer; Oksuzoglu, Berna; Cilbir, Ebru; Cubukcu, Erdem; Cetin, Bulent; Oktay, Esin; Erol, Cihan; Okutur, Sadi Kerem; Yildirim, Nilgun; Alkan, Ali; Selcukbiricik, Fatih; Aksoy, Asude; Karakas, Yusuf; Ozkanli, Gulhan; Duman, Berna Bozkurt; Aydin, Dincer; Dulgar, Ozgecan; Er, Muhammed Muhiddin; Teker, Fatih; Yavuzsen, Tugba; Aykan, Musa Baris; Inal, Ali; Iriagac, Yakup; Kalkan, Nurhan Onal; Keser, Murat; Sakalar, Teoman; Menekse, Serkan; Kut, Engin; Bilgin, Burak; Karaoglanoglu, Muge; Sunar, Veli; Ozdemir, Ozlem; Turhal, Nazim Serdar; Karadurmus, Nuri; Yalcin, Bulent; Sendur, Mehmet Ali Nahit; OYUCU ORHAN, SİBEL; ÇUBUKÇU, ERDEM; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Onkoloji Anabilim Dalı.; 0000-0001-8217-3471 ; ETP-1691-2022; AAJ-8314-2021
    Background: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Methods: The authors report retrospective real-life data for 600 patients with estrogen receptor- and/or progesterone receptor-positive and HER2-negative metastatic breast cancer who were treated with ribociclib and palbociclib in combination with letrozole. Results & conclusion: The results demonstrated that the combination of palbociclib or ribociclib with letrozole has similar progression-free survival and overall survival benefit in real life for the patient group with similar clinical features. Specifically, endocrine sensitivity may be a factor to be considered in the treatment preference.